falsefalse

My Treatment Approach: Metastatic Melanoma - Episode 6

Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab

,

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: The Current State of Metastatic Melanoma
    EP. 2: First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile
    EP. 3: First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab
    EP. 4: First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors
    EP. 5: First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs
    Now Viewing
    EP. 6: Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab
    EP. 7: Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited
    EP. 8: Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios
    EP. 9: Closing Remarks on the Treatment of Patients With Metastatic Melanoma

    Related Content:

    My Treatment Approach: Metastatic MelanomaMelanoma & Skin Cancer
    The OncFive: Top Oncology Articles for the Week of 4/27
    China’s NMPA Approves Toripalimab in First-Line Melanoma
    Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma
    x